Provectus Biopharmaceuticals, Inc. announced that non-clinical data on Provectus?s proprietary, pharmaceutical-grade, rose bengal sodium (?RBS?) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (?SID?), held May 15-18, 2024 in Dallas, Texas. This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (?UTMB?). The UTMB team and Dr. El Ayadi concluded that: The application of multidose 0.01% RBS every other day under ambient light (?RBS treatment?) to full-thickness wounds showed: No toxicity or mortality, No loss in body weight, No organ abnormalities, and No observed adverse effect level at the highest tested dose, Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function, Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing, Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure, RBS treatment: Accelerated wound closure (significant difference at three days), Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, and Reduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis.